Editorial of Special Column“Novel Peptides and Peptidomimetics in Drug Discovery”  

作　　者：Jianfeng Cai Lulu Wei 

机构地区：[1]Department of Chemistry,University of South Florida

出　　处：《Acta Pharmaceutica Sinica B》2021年第9期2606-2608,共3页药学学报（英文版）

摘　　要：Since insulin,a natural peptide composed of 51 amino acids,was first isolated and commercialized in the 1920s,peptide drugs have greatly reshaped our modern drug discovery area^(1).To date,the total number of approved peptide drugs for human use worldwide has exceeded 60^(2).Popular peptide drugs such as liraglutide(Victoza)^(2) and glucagon-like peptide 1(GLP-1)^(3) are the topselling drugs for type 2 diabetes.However,significant hurdles associated with natural peptide sequences as therapeutics,such as metabolic instability and,consequently,have low oral bioavailability and shorter half-life^(4),are still remaining.To overcome the limitations of natural peptides and further optimize their advantages,peptidomimetics emerged as an alternative strategy.

关 键 词：DRUGS POPULAR OVERCOME 

分 类 号：R91[医药卫生—药学]